Please login to the form below

Not currently logged in
Email:
Password:

Antibody drug conjugates

This page shows the latest Antibody drug conjugates news and features for those working in and with pharma, biotech and healthcare.

Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

Daiichi-Sankyo has ambitions to carve out a slice of the HER2 inhibitor market, and is pitting its antibody drug conjugate (ADC) against one of the incumbents – Roche’s Kadcyla – in ... If successful in phase 3, Daiichi-Sankyo’s drug could muscle

Latest news

More from news
Approximately 8 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare

    Current projects include developing antibodies for use as cancer imaging agents, antibody drug conjugates, chimeric antigen receptor therapies (CAR-Ts) and nano-medicines. ... and using efficient AI to generate a set of high-quality drug candidates.

  • Deal Watch February 2016 Deal Watch February 2016

    The antibody, to be known as COR-001, will be progressed for cardiovascular applications. ... This month saw two existing partnerships that have been extended. Takeda has been working with Mersana Therapeutics since 2014 to develop antibody drug

  • Pharma deals in April 2015 Pharma deals in April 2015

    The agreement also includes payment of double digit royalties. Innate also put in place a collaboration with Sanofi for next generation antibody-drug conjugates (ADCs) using Innate's site specific conjugation ... its SAR3419, an antibody-drug conjugate

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 150. Sutro Biopharma/Celgene. Licence plus option to acquire Sutro. For development of multispecific antibodies and antibody drug conjugates (ADCs). ... 475. CureTech/Medivation. Exclusive global licence. For pidilizumab (CT-011), an immune modulatory

  • Pharma deals during October 2014 Pharma deals during October 2014

    An oncology deal for multispecific antibodies and antibody drug conjugates [ADCs], this transaction builds on the original deal signed in December 2012 with a headline of $500m. ... Keeping it flexible, Roche extended its 2013 licence agreement with

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Crescendo Biologics appoints Peter Pack as CEO Crescendo Biologics appoints Peter Pack as CEO

    Crescendo is now shifting its focus to oncology with novel VH-based checkpoint modulators and humabody drug conjugate (HDC) therapeutics. ... We intend to expand rapidly our internal oncology programmes on checkpoint modulators and HDCs, which are a

  • ADC Therapeutics expands team ADC Therapeutics expands team

    ADC Therapeutics expands team. Appointments preceed its first antibody drug conjugate trials. ... ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development.

  • ImmunoGen hires VP product strategy ImmunoGen hires VP product strategy

    These programmes focus on antibody-drug conjugates (ADCs) to target cancers. The most successful of these ADCs so far is Kadcyla, which ImmunoGen developed with Genentech, now a part of Roche.

  • AVEO's financial head joins ImmunoGen AVEO's financial head joins ImmunoGen

    In his new role, Johnston will head the financial operations of one of the leading biotechs working to develop antibody-drug conjugates in cancer, with ImmunoGen's successes including the breast

  • CytomX makes senior changes following Pfizer deal CytomX makes senior changes following Pfizer deal

    CytomX Therapeutics has boosted both its senior science and business teams following a major antibody deal with Pfizer. ... Both positions will be crucial to supporting the San Francisco-based biotech's growth following CytomX's  $635m deal agreed with

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics